Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Global Infantile Spasm Treatment Market, by Product Type (Adrenocorticotropic Hormone, Vigabatrin, and Phase III), By Route of Administration (Oral and Parenteral), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 111.1 million in 2017 and is projected to exhibit a CAGR of 3.1% during the forecast period (2018 – 2026), as highlighted in a new report published by Coherent Market Insights.
Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/2453
Strong product pipeline and launch of cost-effective generic versions of existing drugs by market players is expected to augment the market growth
Key players in the market are focused on launching cost-effective generic drugs to treat infantile spasm and address the critical unmet needs of patients. For instance, in May 2018, Amneal Pharmaceuticals launched vigabatrin for oral solution USP, which is a generic equivalent for Sabril. This is the second generic vigabatrin product available in the market. Aucta Pharmaceuticals and Upsher-Smith Laboratories, LLC launched vigabatrin for oral solution under the brand name Vigadrone in July 2018, which is another generic version of vigabatrin (Sabril).
Browse 39 Market Data Tables and 29 Figures spread through 150 Pages and in-depth TOC on Infantile Spasm Treatment, by Product Type (Adrenocorticotropic Hormone, Vigabatrin, and Phase III), By Route of Administration (Oral and Parenteral), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Global Forecast to 2026
To know the latest trends and insights in the Infant Spasm Treatment market Press Release, click the link below: https://bit.ly/2HoqL0B
As of 2018, there were around 5 novel drug candidates in development. 60% of these drugs are in phase III of development which are expected to enter the market in the near future, thereby offering effective treatment among the fastest-growing markets in the world.
Key players operating in the market are focused on adopting strategies such as mergers and acquisitions to enhance their product portfolio. For instance, in April 2014, Mallinckrodt Pharmaceuticals acquired Questcor, a company involved in contract manufacturing services. Questcor owns the FDA approved H.P. Acthar Gel, an injectable drug for 19 indications including treatment of infantile spasm.
Apply Promo Code “STAYHOME” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2453
Key Takeaways of the Infantile Spasm Treatment Market:
- The global infantile spasm treatment market is expected to exhibit a CAGR of 3.1% during the forecast period owing to the increasing prevalence of cardiopulmonary conditions, cancer, and renal diseases
- Among product type, the adrenocorticotropic hormone (ACTH) segment held a dominant position in the infantile spasm treatment market in 2018 owing to low side effects and greater efficacy than other medications
- Among route of administration, parenteral segment held dominant position in the infant spasm treatment market in 2018, as the effective drug adrenocorticotropic hormone (ACTH) is available in parenteral form
- Key players operating in the global infantile spasm market are H. Lundbeck A/S, Mallinckrodt Pharmaceuticals, Anavex Life Sciences Corp., Catalyst Pharmaceuticals, GW Pharmaceuticals plc., and Retrophin, Inc., Valerion Therapeutics, Orphelia Pharma SA, Insys Therapeutics Inc., Etrophin Inc., and Catalystpharma.
Other Exclusive Reports:
